Bessemer Group
KYMR icon

Bessemer Group’s Kymera Therapeutics KYMR Stock Holding History

Bessemer Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
928
– – ﹤0.01% 1513
2026
Q1 		$77K Sell
928
-22
-2% -$1.74K ﹤0.01% 1560
2025
Q4 		$74K Buy
950
+10
+1% +$675 ﹤0.01% 1533
2025
Q3 		$53K Buy
940
+815
+652% +$36.8K ﹤0.01% 1425
2025
Q2 		$5K Buy
125
+65
+108% +$2.24K ﹤0.01% 2026
2025
Q1 		$2K Sell
60
-5
-8% -$182 ﹤0.01% 2243
2024
Q4 		$3K Hold
65
– – ﹤0.01% 2131
2024
Q3 		$3K Buy
+65
New +$2.87K ﹤0.01% 2104

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bessemer Group's KYMR Position: Q2 2026 in Review

Bessemer Group held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 928 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

Bessemer Group first reported a position in KYMR in Q3 2024 and has held it in 8 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Bessemer Group held 928 shares of Kymera Therapeutics worth $106K as of Q2 2026.
  • Bessemer Group left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1513 holding.
  • Bessemer Group first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.